# A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

> **NCT00507507** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 126 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir DF
- **DRUG:** FTC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00507507
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-02
- **Final completion:** 2012-08
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2015-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00507507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00507507, "A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00507507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*